Serum soluble fms‐like tyrosine kinase‐1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history

Abstract

ABSTRACT

Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation

“…Gestational age at delivery with PE was defined by two components: firstly, the prior distribution based on maternal factors and secondly, the conditional distribution of MoM biomarker values given the gestational age with PE and maternal factors. Values of MAP, UtA‐PI, PlGF and sFlt‐1 were expressed as MoMs adjusting for those characteristics found to provide a substantive contribution to their values, including the maternal factors in the prior model. Multivariable Gaussian distributions were fitted to the log 10 MoM values of the biomarkers and a common covariance matrix was assumed for these distributions.…”

Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome

“…The measured values of UtA‐PI, UA‐PI, MCA‐PI, MAP, PlGF and sFlt‐1 were expressed as multiples of the median (MoM) after adjusting for variables from maternal characteristics and medical history that affect these measurements. Univariable and multivariable logistic regression analysis was used to determine if log 10 MoM of each biomarker had a significant contribution in predicting each adverse outcome.…”

Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome

“…The measured values of UtA‐PI, UA‐PI, MCA‐PI, MAP, PlGF and sFlt‐1 were expressed as multiples of the median (MoM) after adjustment for variables from maternal characteristics and medical history that affect these measurements. Univariable and multivariable logistic regression analyses were used to determine if log 10 MoM of each biomarker had a significant contribution in predicting each adverse outcome.…”